Jan 27 (Reuters) - European Medicines Agency:
* EMA RECOMMENDS CONDITIONAL MARKETING AUTHORISATION FOR PAXLOVID
* EMA: CHMP RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR ORAL ANTIVIRAL MEDICINE PAXLOVID FOR THE TREATMENT OF COVID-19
* EMA: RECOMMENDED PAXLOVID FOR TREATING COVID-19 IN ADULTS WHO DO NOT REQUIRE SUPPLEMENTAL OXYGEN AND ARE AT INCREASED RISK OF SEVERE DISEASE
* EMA SAYS PAXLOVID IS THE FIRST ANTIVIRAL MEDICINE TO BE GIVEN BY MOUTH THAT IS RECOMMENDED IN THE EU FOR TREATING COVID-19.
* EMA SAYS PAXLOVID IS ALSO EXPECTED TO BE ACTIVE AGAINST OMICRON AND OTHER VARIANTS.
* EMA: SAFETY PROFILE OF PAXLOVID WAS FAVOURABLE AND SIDE EFFECTS WERE GENERALLY MILD
* EMA: MAJORITY OF PATIENTS IN STUDY WERE INFECTED WITH THE DELTA VARIANT; BASED ON LAB STUDIES, PAXLOVID ALSO EXPECTED TO BE ACTIVE AGAINST OMICRON
* EMA: RITONAVIR IS KNOWN TO AFFECT ACTION OF MANY OTHER MEDICINES, AND WARNINGS AND ADVICE HAVE BEEN INCLUDED IN PAXLOVID’S PRODUCT INFORMATION
* EMA: CHMP CONCLUDED THAT PAXLOVID'S BENEFITS ARE GREATER THAN ITS RISKS FOR THE APPROVED USE Further company coverage:
